⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20284333 | 0.84 | — | — | |
| SCHEMBL13621437 | 0.84 | — | — | |
| SCHEMBL24801877 | 0.79 | — | — | |
| SCHEMBL20731168 | 0.77 | — | — | |
| SCHEMBL2139141 | 0.68 | — | — | |
| SCHEMBL20826623 | 0.67 | PIK3CD (0.38) | — | |
| SCHEMBL24801838 | 0.67 | — | — | |
| SCHEMBL4546583 | 0.67 | PIK3CD (0.38) | — | |
| SCHEMBL21377281 | 0.67 | — | — | |
| SCHEMBL17719320 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105553-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024079623-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2024-04-18 | — | — | WO | disclosed |
| US-20230026616-A1 | PYRIMIDOIMIDAZOLE COMPOUNDS USED AS DNA-PK INHIBITORS | ZAI LAB (SHANGHAI) CO., LTD (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3863713-B1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021104277-A1 | PYRIMIDOIMIDAZOLE COMPOUNDS USED AS DNA-PK INHIBITORS | 南京明德新药研发有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2020035540-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-02-20 | — | — | WO | disclosed |